<DOC>
	<DOCNO>NCT00498667</DOCNO>
	<brief_summary>A retrospective analysis perform regard usefulness PET/CT perform follow 2 cycle chemotherapy evaluation progression , free survival overall survival patient aggressive non Hodgkin Lymphoma .</brief_summary>
	<brief_title>The Prognostic Value Interim PET/CT After 2 Cycles Chemotherapy Predicting Progression Non Hodgkins Lymphoma</brief_title>
	<detailed_description>Patients treat aggressive non-Hodgkin lymphoma adriamycin contain regimen , CHOP High dose CHOP without rituximab evaluate post 2 cycle chemotherapy rule disease progression . Currently retrospective evaluation PET/CT predictive value progression free survival overall survival evaluate</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>aggressive nonHodgkin lymphoma b cell age 1870 bilirubin le 2 creatinine less 2 Pet/CT perform post 2 cycle PET/CT post 2 cycle perform bilirubin &gt; 2 creatinine 2 HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PET/CT</keyword>
	<keyword>Aggressive non-Hodgkin Lymphoma</keyword>
</DOC>